WBC reduction in RBC concentrates by prestorage filtration: Multicenter experience

Roslyn Yomtovian, Terry Gernsheimer, Susan F. Assmann, Kala Mohandas, Tzong Hae Lee, Leslie A. Kalish, Michael P. Busch

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

BACKGROUND: As universal leukocyte (WBC) reduction (ULR) is being considered as a new standard, few data are available on the performance of WBC-reduction filtration in routine practice. The performance of WBC-reduction in RBCs, using varied filtration practices, in meeting the current FDA requirement (<5 × 106). Council of Europe (EC) recommendation, the proposed FDA requirement (<1 × 106), and a more stringent proposal (<5 × 105) for residual WBCs per RBC unit was assessed and compared. STUDY DESIGN AND METHODS: Participating facilities were the 11 sites of the Viral Activation Transfusion Study (VATS), a prospective study of the impact of transfusion with and without WBC-reduction on survival and HIV viral load in HIV-1-infected patients. Patients randomly assigned to undergo WBC reduction were required to receive RBCs <14 days old that had undergone prestorage (within 72 hours of collection) WBC-reduction filtration by a method devised to achieve a postf iltration WBC count of <5 × 106. Residual WBC quantitation was performed by PCR in the central VATS laboratory by using frozen WBC-reduced RBC samples obtained at issue for transfusion. RESULTS: A total of 1869 WBC-reduced RBC units were studied. Filtration practices varied within and between sites. There were significant differences in mean residual WBC counts at the 11 sites (p<0.001). Among the WBC-reduced RBC units, 0.8 percent exceeded 5 × 106 WBCs per unit, 8.3 percent exceeded 1 × 106 WBCs per unit, and 14.3 percent exceeded 5 × 105 WBCs per unit. CONCLUSION: Residual WBCs in WBC-reduced RBC units vary within and between sites. WBC reduction was successful, in that over 99 percent and 91 percent of VATS WBC-reduced RBC units met US and EC thresholds, respectively. However, the small but measurable failure rate indicates that not every unit will meet these guidelines.

Original languageEnglish (US)
Pages (from-to)1030-1036
Number of pages7
JournalTransfusion
Volume41
Issue number8
DOIs
StatePublished - Aug 2001
Externally publishedYes

Fingerprint

Virus Activation
Viral Load
HIV-1
Leukocytes
HIV
Prospective Studies
Guidelines
Polymerase Chain Reaction
Survival

ASJC Scopus subject areas

  • Immunology
  • Hematology

Cite this

Yomtovian, R., Gernsheimer, T., Assmann, S. F., Mohandas, K., Lee, T. H., Kalish, L. A., & Busch, M. P. (2001). WBC reduction in RBC concentrates by prestorage filtration: Multicenter experience. Transfusion, 41(8), 1030-1036. https://doi.org/10.1046/j.1537-2995.2001.41081030.x

WBC reduction in RBC concentrates by prestorage filtration : Multicenter experience. / Yomtovian, Roslyn; Gernsheimer, Terry; Assmann, Susan F.; Mohandas, Kala; Lee, Tzong Hae; Kalish, Leslie A.; Busch, Michael P.

In: Transfusion, Vol. 41, No. 8, 08.2001, p. 1030-1036.

Research output: Contribution to journalArticle

Yomtovian, R, Gernsheimer, T, Assmann, SF, Mohandas, K, Lee, TH, Kalish, LA & Busch, MP 2001, 'WBC reduction in RBC concentrates by prestorage filtration: Multicenter experience', Transfusion, vol. 41, no. 8, pp. 1030-1036. https://doi.org/10.1046/j.1537-2995.2001.41081030.x
Yomtovian, Roslyn ; Gernsheimer, Terry ; Assmann, Susan F. ; Mohandas, Kala ; Lee, Tzong Hae ; Kalish, Leslie A. ; Busch, Michael P. / WBC reduction in RBC concentrates by prestorage filtration : Multicenter experience. In: Transfusion. 2001 ; Vol. 41, No. 8. pp. 1030-1036.
@article{8b34c49cff2741b48bcb5024f36456fc,
title = "WBC reduction in RBC concentrates by prestorage filtration: Multicenter experience",
abstract = "BACKGROUND: As universal leukocyte (WBC) reduction (ULR) is being considered as a new standard, few data are available on the performance of WBC-reduction filtration in routine practice. The performance of WBC-reduction in RBCs, using varied filtration practices, in meeting the current FDA requirement (<5 × 106). Council of Europe (EC) recommendation, the proposed FDA requirement (<1 × 106), and a more stringent proposal (<5 × 105) for residual WBCs per RBC unit was assessed and compared. STUDY DESIGN AND METHODS: Participating facilities were the 11 sites of the Viral Activation Transfusion Study (VATS), a prospective study of the impact of transfusion with and without WBC-reduction on survival and HIV viral load in HIV-1-infected patients. Patients randomly assigned to undergo WBC reduction were required to receive RBCs <14 days old that had undergone prestorage (within 72 hours of collection) WBC-reduction filtration by a method devised to achieve a postf iltration WBC count of <5 × 106. Residual WBC quantitation was performed by PCR in the central VATS laboratory by using frozen WBC-reduced RBC samples obtained at issue for transfusion. RESULTS: A total of 1869 WBC-reduced RBC units were studied. Filtration practices varied within and between sites. There were significant differences in mean residual WBC counts at the 11 sites (p<0.001). Among the WBC-reduced RBC units, 0.8 percent exceeded 5 × 106 WBCs per unit, 8.3 percent exceeded 1 × 106 WBCs per unit, and 14.3 percent exceeded 5 × 105 WBCs per unit. CONCLUSION: Residual WBCs in WBC-reduced RBC units vary within and between sites. WBC reduction was successful, in that over 99 percent and 91 percent of VATS WBC-reduced RBC units met US and EC thresholds, respectively. However, the small but measurable failure rate indicates that not every unit will meet these guidelines.",
author = "Roslyn Yomtovian and Terry Gernsheimer and Assmann, {Susan F.} and Kala Mohandas and Lee, {Tzong Hae} and Kalish, {Leslie A.} and Busch, {Michael P.}",
year = "2001",
month = "8",
doi = "10.1046/j.1537-2995.2001.41081030.x",
language = "English (US)",
volume = "41",
pages = "1030--1036",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - WBC reduction in RBC concentrates by prestorage filtration

T2 - Multicenter experience

AU - Yomtovian, Roslyn

AU - Gernsheimer, Terry

AU - Assmann, Susan F.

AU - Mohandas, Kala

AU - Lee, Tzong Hae

AU - Kalish, Leslie A.

AU - Busch, Michael P.

PY - 2001/8

Y1 - 2001/8

N2 - BACKGROUND: As universal leukocyte (WBC) reduction (ULR) is being considered as a new standard, few data are available on the performance of WBC-reduction filtration in routine practice. The performance of WBC-reduction in RBCs, using varied filtration practices, in meeting the current FDA requirement (<5 × 106). Council of Europe (EC) recommendation, the proposed FDA requirement (<1 × 106), and a more stringent proposal (<5 × 105) for residual WBCs per RBC unit was assessed and compared. STUDY DESIGN AND METHODS: Participating facilities were the 11 sites of the Viral Activation Transfusion Study (VATS), a prospective study of the impact of transfusion with and without WBC-reduction on survival and HIV viral load in HIV-1-infected patients. Patients randomly assigned to undergo WBC reduction were required to receive RBCs <14 days old that had undergone prestorage (within 72 hours of collection) WBC-reduction filtration by a method devised to achieve a postf iltration WBC count of <5 × 106. Residual WBC quantitation was performed by PCR in the central VATS laboratory by using frozen WBC-reduced RBC samples obtained at issue for transfusion. RESULTS: A total of 1869 WBC-reduced RBC units were studied. Filtration practices varied within and between sites. There were significant differences in mean residual WBC counts at the 11 sites (p<0.001). Among the WBC-reduced RBC units, 0.8 percent exceeded 5 × 106 WBCs per unit, 8.3 percent exceeded 1 × 106 WBCs per unit, and 14.3 percent exceeded 5 × 105 WBCs per unit. CONCLUSION: Residual WBCs in WBC-reduced RBC units vary within and between sites. WBC reduction was successful, in that over 99 percent and 91 percent of VATS WBC-reduced RBC units met US and EC thresholds, respectively. However, the small but measurable failure rate indicates that not every unit will meet these guidelines.

AB - BACKGROUND: As universal leukocyte (WBC) reduction (ULR) is being considered as a new standard, few data are available on the performance of WBC-reduction filtration in routine practice. The performance of WBC-reduction in RBCs, using varied filtration practices, in meeting the current FDA requirement (<5 × 106). Council of Europe (EC) recommendation, the proposed FDA requirement (<1 × 106), and a more stringent proposal (<5 × 105) for residual WBCs per RBC unit was assessed and compared. STUDY DESIGN AND METHODS: Participating facilities were the 11 sites of the Viral Activation Transfusion Study (VATS), a prospective study of the impact of transfusion with and without WBC-reduction on survival and HIV viral load in HIV-1-infected patients. Patients randomly assigned to undergo WBC reduction were required to receive RBCs <14 days old that had undergone prestorage (within 72 hours of collection) WBC-reduction filtration by a method devised to achieve a postf iltration WBC count of <5 × 106. Residual WBC quantitation was performed by PCR in the central VATS laboratory by using frozen WBC-reduced RBC samples obtained at issue for transfusion. RESULTS: A total of 1869 WBC-reduced RBC units were studied. Filtration practices varied within and between sites. There were significant differences in mean residual WBC counts at the 11 sites (p<0.001). Among the WBC-reduced RBC units, 0.8 percent exceeded 5 × 106 WBCs per unit, 8.3 percent exceeded 1 × 106 WBCs per unit, and 14.3 percent exceeded 5 × 105 WBCs per unit. CONCLUSION: Residual WBCs in WBC-reduced RBC units vary within and between sites. WBC reduction was successful, in that over 99 percent and 91 percent of VATS WBC-reduced RBC units met US and EC thresholds, respectively. However, the small but measurable failure rate indicates that not every unit will meet these guidelines.

UR - http://www.scopus.com/inward/record.url?scp=0035431165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035431165&partnerID=8YFLogxK

U2 - 10.1046/j.1537-2995.2001.41081030.x

DO - 10.1046/j.1537-2995.2001.41081030.x

M3 - Article

C2 - 11493735

AN - SCOPUS:0035431165

VL - 41

SP - 1030

EP - 1036

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 8

ER -